The Future of Cardiac Surgery
A GLOBAL HEALTH PROBLEM

Today an estimated 82 million Americans suffer from 1 or more types of cardiovascular disease (CVD) and it is the cause of 1 out of every 6 deaths in the US. And every year, well over 250,000 Americans undergo coronary artery bypass surgery to mitigate its effects. The total economic burden of CVD is staggering, exceeding $286.6 billion in 2007. (Source:AHA Heart Disease and Stroke 2012 Update).

In 27 member states of the European Union (EU) the burden of CVD is also significant as it remains the main cause of death, contributing to over 2.0 million deaths each year. The death rates are generally higher in Central and Eastern Europe. The total cost of CVD to the EU economy is estimated at €192 billion a year. (Source: European Cardiovascular Disease Statistics: 2008 Edition)

INNOVATIVE TREATMENT OPTIONS ARE HERE

Kips Bay Medical is dedicated to providing therapeutic vascular technologies for the cardiac surgeon to better treat cardiovascular disease. We are at the forefront of developing innovative solutions designed to advance, refine and improve cardiac surgery.

The company’s first commercial product is the eSVS Mesh – a metal alloy prosthesis which is designed to maintain patency of saphenous vein grafts used in the coronary artery bypass surgery (CABG).

eSVS Mesh represents the future of cardiac surgery: a simple, easy-to-use device designed to enhance the surgeon’s ability to optimize patient outcomes without adding significantly to the time of CABG procedures.

Caution: Investigational Device Limited by Federal (or United States) law to investigational use
This device is commercially available for use in select international markets

 
 
Our Mission
To advance, refine and improve cardiac surgery